ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,053.78
0.05%
Dow Jones
43,570.70
0.28%
US Dollar vs MXN
20.1479
-0.15%
Brent Oil
73.865
1.04%
Bitcoin
103,576.77
-2.43%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) Noticias

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KPTI
FechaHoraFuenteTítuloSímboloCompañía
16/12/202415:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
09/12/202407:00PR Newswire (US)Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202415:35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202406:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202406:00PR Newswire (US)Karyopharm Therapeutics Provides Endometrial Cancer Program UpdateNASDAQ:KPTIKaryopharm Therapeutics Inc
02/12/202406:00PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
25/11/202406:00PR Newswire (US)Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
22/11/202415:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
20/11/202415:05PR Newswire (US)Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
14/11/202415:22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202407:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202406:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202406:30PR Newswire (US)Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202407:00PR Newswire (US)Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202406:30PR Newswire (US)Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202415:30PR Newswire (US)Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
03/09/202406:00PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/08/202406:30PR Newswire (US)Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
31/07/202415:05PR Newswire (US)Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
19/07/202415:07Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
20/06/202407:01Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:KPTIKaryopharm Therapeutics Inc
09/06/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KPTIKaryopharm Therapeutics Inc
01/06/202412:45PR Newswire (US)Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesNASDAQ:KPTIKaryopharm Therapeutics Inc
30/05/202415:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KPTIKaryopharm Therapeutics Inc
29/05/202415:05PR Newswire (US)Karyopharm to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
23/05/202415:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202415:05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202406:30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202406:30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Su Consulta Reciente

COIN
ADAUSD
Cardano
NASDAQ
NVDA
NVIDIA
NYSE
VZ
Verizon Communications
FX
EURMXN
Euro vs MXN
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
NYSE
JPM
JP Morgan Chase
NYSE
MCD
McDonalds
COIN
SOLUSD
Solana
CCOM
US30
US 30
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
CCOM
OILBRENT
Brent Oil
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados